Mubadala Invests in Global Biosimulation Leader Certara

Princeton, N.J., July 27, 2021: Certara (NASDAQ: CERT), a global leader in biosimulation, today announced that Mubadala Investment Company (Mubadala) has made an approximately $250 million investment in Certara.  The investment aligns with Mubadala’s strategy of enabling innovation to address unmet clinical needs and drive cost efficiencies. Mubadala and certain existing institutional shareholders of Certara, including … Continued

Certara Appoints Dr. Carol Gallagher as New Independent Board Member

Dr. Gallagher brings more than 30 years of drug development and commercial leadership experience to her new role PRINCETON, N.J.—June 14, 2021.  Certara, a global leader in biosimulation, today announced the addition of Carol Gallagher, Pharm.D., to its board of directors.  Dr. Gallagher is an experienced biopharmaceutical director and operator and serves as a venture … Continued

Certara Acquires UK-based Insight Medical Writing

Expands global reach and deepens regulatory expertise PRINCETON, NJ.— June 10, 2021– Certara, Inc., the global leader in biosimulation, today announced the acquisition of Insight Medical Writing, based in Oxford in the United Kingdom.  Financial terms of the transaction were not disclosed. Founded in 2002, Insight Medical Writing offers regulatory services and medical writing. Its … Continued

Certara Releases New Versions of Its Preeminent Quantitative Systems Pharmacology (QSP) Simulators for Expediting Development of Biologics and Immuno-oncology Therapies

Expanded capabilities in company’s Immunogenicity and Immuno-oncology QSP Simulators broaden applicability for addressing safety and efficacy challenges PRINCETON, N.J., May 13, 2021 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), the global leader in biosimulation, today announced the launch of new versions of its Immunogenicity (IG) and Immuno-oncology (IO) Quantitative Systems Pharmacology (QSP) Simulators to help address … Continued

Certara Announces Pricing of Public Offering of Common Stock

PRINCETON, N.J.—March 24, 2021. Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of 10 million shares of its common stock by certain existing stockholders (“the selling stockholders”) at a price to the public of $25.00 per share.  Additionally, the selling stockholders have granted the underwriters … Continued

Certara Renews Peking Union Medical College Hospital as Academic Center of Excellence for Model-Informed Drug Development

Partnership provides access to Certara’s industry-standard Phoenix™ Platform to advance drug development in China PRINCETON, N.J.—Mar 1 , 2021. Certara, a global leader in biosimulation, today announced that it has renewed Peking Union Medical College Hospital (PUMCH) as an academic Center of Excellence for model-informed drug development. Through this partnership, Certara will provide training and access … Continued

Certara Releases Simcyp™ PBPK Simulator Version 20, Including Newly Expanded Biologics Software

Unique capabilities expand the types of drugs, modalities, populations, and development questions modeled using the Simcyp PBPK Simulator   PRINCETON, NJ.— January 27, 2021– Certara, Inc., the global leader in biosimulation, today announced the release of version 20 of its Simcyp™ Physiologically-based Pharmacokinetic (PBPK) Simulator platform.  Simcyp PBPK Simulator version 20 provides new models for … Continued

Certara Announces Closing of its Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

PRINCETON, NJ.— December 16, 2020 – Certara, Inc. (“Certara”), a global leader in biosimulation by 2019 revenue, today announced that on December 15, 2020, it closed its upsized initial public offering of 33,413,250 shares of common stock at $23.00 per share. The closing includes 4,358,250 shares sold upon full exercise of the underwriters’ option to … Continued

Hedging the vaccine bet

It’s a race that the public, government, health officials and Wall Street are watching intently, happening in labs worldwide, where researchers work, day and night, to develop coronavirus vaccines. By the World Health Organization’s current count, 44 vaccines are undergoing clinical trials, with 154 candidates in preclinical development. The work happening in vaccine development is inspiring and groundbreaking. ..

RACE for Children Act Opens New Avenues for Pediatric Oncology Drug Development

With the long-anticipated ignition of the Research to Accelerate Cures and Equity (RACE) for Children Act on Tuesday (August 18) this week, stakeholders in the development of oncology drugs—ranging from patients and their families to clinical research sponsors and practitioners—have new hopes for advancements in more effective therapies for pediatric cancers. According to Lynne Georgopoulos, … Continued

1 of 8
Back to top
Powered by GlobalLink OneLink Software